MX2021011529A - Chiauranib para el tratamiento de cáncer de pulmón microcítico. - Google Patents

Chiauranib para el tratamiento de cáncer de pulmón microcítico.

Info

Publication number
MX2021011529A
MX2021011529A MX2021011529A MX2021011529A MX2021011529A MX 2021011529 A MX2021011529 A MX 2021011529A MX 2021011529 A MX2021011529 A MX 2021011529A MX 2021011529 A MX2021011529 A MX 2021011529A MX 2021011529 A MX2021011529 A MX 2021011529A
Authority
MX
Mexico
Prior art keywords
chiauranib
lung cancer
small cell
cell lung
treatment
Prior art date
Application number
MX2021011529A
Other languages
English (en)
Inventor
Desi Pan
Song Shan
Xianping Lu
Zhiqiang Ning
Original Assignee
Shenzhen Chipscreen Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences Co Ltd filed Critical Shenzhen Chipscreen Biosciences Co Ltd
Publication of MX2021011529A publication Critical patent/MX2021011529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulga un método para tratar cáncer de pulmón microcítico mediante el uso de chiauranib y el uso de chiauranib en la preparación de un fármaco para tratar cáncer de pulmón microcítico.
MX2021011529A 2019-03-25 2020-03-18 Chiauranib para el tratamiento de cáncer de pulmón microcítico. MX2021011529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910229379 2019-03-25
PCT/CN2020/079822 WO2020192506A1 (zh) 2019-03-25 2020-03-18 西奥罗尼用于小细胞肺癌的治疗

Publications (1)

Publication Number Publication Date
MX2021011529A true MX2021011529A (es) 2021-12-15

Family

ID=72611382

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011529A MX2021011529A (es) 2019-03-25 2020-03-18 Chiauranib para el tratamiento de cáncer de pulmón microcítico.

Country Status (12)

Country Link
US (1) US20220184055A1 (es)
EP (1) EP3949966A4 (es)
JP (1) JP7278405B2 (es)
KR (1) KR20210141643A (es)
CN (2) CN115105501A (es)
AU (1) AU2020248270B2 (es)
BR (1) BR112021018858A2 (es)
CA (1) CA3134156C (es)
MX (1) MX2021011529A (es)
TW (2) TWI797426B (es)
WO (1) WO2020192506A1 (es)
ZA (1) ZA202107342B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI797426B (zh) * 2019-03-25 2023-04-01 大陸商深圳微芯生物科技股份有限公司 西奧羅尼用於小細胞肺癌的治療
WO2023160647A1 (zh) * 2022-02-24 2023-08-31 康方药业有限公司 包含抗ctla4-抗pd-1双特异性抗体和西奥罗尼的药物组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101906076B (zh) * 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CN105481778B (zh) * 2014-09-16 2019-06-04 深圳微芯生物科技股份有限公司 嘧啶衍生物、其制备方法及其应用
CN111065411B (zh) * 2017-11-16 2023-03-10 江苏恒瑞医药股份有限公司 Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
TWI798532B (zh) * 2019-03-25 2023-04-11 大陸商深圳微芯生物科技股份有限公司 Ｋｄｍ５ａ基因和ａｔｒｘ基因的應用
TWI797426B (zh) * 2019-03-25 2023-04-01 大陸商深圳微芯生物科技股份有限公司 西奧羅尼用於小細胞肺癌的治療

Also Published As

Publication number Publication date
CA3134156A1 (en) 2020-10-01
CN111728974B (zh) 2022-08-16
AU2020248270B2 (en) 2023-05-18
WO2020192506A1 (zh) 2020-10-01
JP2022527702A (ja) 2022-06-03
EP3949966A1 (en) 2022-02-09
CA3134156C (en) 2024-01-16
BR112021018858A2 (pt) 2022-01-11
JP7278405B2 (ja) 2023-05-19
TWI797426B (zh) 2023-04-01
KR20210141643A (ko) 2021-11-23
TW202332445A (zh) 2023-08-16
TW202034919A (zh) 2020-10-01
CN115105501A (zh) 2022-09-27
US20220184055A1 (en) 2022-06-16
CN111728974A (zh) 2020-10-02
EP3949966A4 (en) 2022-12-28
ZA202107342B (en) 2023-03-29
AU2020248270A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
EP3953379A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING MODIFIED TET2 T LYMPHOCYTE CELL THERAPY
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2020003719A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
MX2020009773A (es) Terapia de combinacion.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MY202377A (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
MX2020001727A (es) Terapia de combinacion.
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
MX2019013862A (es) Terapia de combinacion.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
MX2021011529A (es) Chiauranib para el tratamiento de cáncer de pulmón microcítico.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.